Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience
Journal of Cancer Research and Clinical Oncology · 2025
DOI: 10.1007/s00432-025-06406-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Keitaro Shimozaki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Ariake 3-8-3, Koto-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Stomach Neoplasms, Claudins, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: This study evaluated the safety and preliminary efficacy of zolbetuximab plus chemotherapy in patients with claudin 18 isoform 2 (CLDN18.2)-positive advanced gastric cancer (AGC). METHODS: This single-institutional retrospective study enrolled patients with HER2-negative CLDN18.2-positive AGC who were treated with zolbetuximab plus chemotherapy between July 2024 and August 2025. RESULTS: The cohort included 50 patients with a median age of 63 years (range 30-83; 44% male). The primary tumor location was the stomach in 86% of the patients. Meanwhile, 26% of the patients underwent prior gastrectomy. The PD-L1 combined positive score was < 5 in 87% of patients. Among 24 patients with measurable lesions at baseline, the objective response and disease control rates were 66.7% and 87.5%, respectively. After median follow-up of 7.3 months, median progression-free survival and the duration of response were 6.7 [95% confidence interval (CI) 5.3-10.7] and 6.7 months (95% CI 4.7-10.2), respectively. Grade ≥ 3 treatment-emergent adverse events occurred in 62% of the patients, most commonly hypoalbuminemia (22%), neutrophil count decreased (22%) and anorexia (12%). Subsequent treatment was received by 83% of the patients. CONCLUSIONS: Zolbetuximab plus chemotherapy was administered to real-world patients with CLDN18.2-positive AGC with acceptable safety profiles and showed preliminary antitumor efficacy. Nevertheless, some adverse events warrant careful monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Ariake 3-8-3, Koto-ku, Tokyo, Japan.
- Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
- Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Ariake 3-8-3, Koto-ku, Tokyo, Japan. akira.oki@jfcr.or.jp.
Zitieren
APA
Shimozaki, K., Ooki, A., Fukuoka, S., Osumi, H., Yoshikawa, K., Yoshino, K., Udagawa, S., Wakatsuki, T., Shinozaki, E., Ogura, M., Chin, K., & Yamaguchi, K. (2025). Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06406-4
Vancouver
Shimozaki K, Ooki A, Fukuoka S, Osumi H, Yoshikawa K, Yoshino K, et al. Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06406-4
BibTeX
@article{Shimozaki2025,
author = {Shimozaki, Keitaro and Ooki, Akira and Fukuoka, Shota and Osumi, Hiroki and Yoshikawa, Kaoru and Yoshino, Koichiro and Udagawa, Shohei and Wakatsuki, Takeru and Shinozaki, Eiji and Ogura, Mariko and Chin, Keisho and Yamaguchi, Kensei},
title = {Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2025},
doi = {10.1007/s00432-025-06406-4}
}
EUVIMED